Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Defence Therapeutics Inc (CSE: DTC )

0.5200 UNCHANGED
Official Closing Price Updated: 2:44 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 250
Open 0.5200
Bid (Size) 0.5100 (22,000)
Ask (Size) 0.5700 (7,000)
Prev. Close 0.5200
Today's Range 0.5200 - 0.5200
52wk Range 0.4800 - 2.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision Medicine Helps Conquer Advanced-Stage Cancer
As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According... 
Via PressReach
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in 
Via PressReach
Exposures Product Safety

Performance

YTD
-77.78%
-77.78%
1 Month
-14.75%
-14.75%
3 Month
-20.00%
-20.00%
6 Month
-55.56%
-55.56%
1 Year
-80.74%
-80.74%

More News

Read More
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Via FinancialNewsMedia
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Via PressReach
Topics Intellectual Property
Exposures Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
Via FinancialNewsMedia
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
Via PressReach
Exposures Product Safety
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Via PressReach
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
Via PressReach
Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
Via PressReach
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Via PressReach
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
Via PressReach
Exposures COVID-19
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
Via PressReach
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Via PressReach
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
Via Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
Via Newsfile
Topics Supply Chain
Exposures Supply Chain
BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals
Via Newsfile
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
Via Newsfile
Topics Death Intellectual Property
Exposures Death Intellectual Property
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Via Newsfile
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
Via Newsfile
The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
Via Newsfile
Exposures COVID-19
Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
Via Newsfile
Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
Via Newsfile
Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic
Via Newsfile
Exposures Product Safety
RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
Via Newsfile
Exposures COVID-19
Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
Via Newsfile
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.